A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease

Exclusion Criteria

• •1. Patients who is scheduled surgery due to coronary artery disease or cerebral infarction disease.
• •2. Patients who have taken aspirin within two weeks before randomization
• •3. Patients who need antiplatelet or anticoagulant medication except Aspirin
• •4. Confirmed below results at screening
• •* Hemoglobin \<13g/dL
• •* Platelet \<60,000/µL
• •* Severe kidney disease patient with eGFR(estimated Glomerular Filtration Rate) \<30 mL/min/1.73 m2 (CKD-EPI)
• •5. Patients with a history of cerebrovascular and cardiovascular complications (brain infarction, transient cerebral ischemic seizures, myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary artery intervention) within the last six months
• •6. Patients with bleeding
• •7. Pregnant or lactating women
• •8. Those participating in other clinical trials for investigational products
• •9. Patients deemed to be ineligible to participate in the trial by investigator